Preparation of Long-Acting Somatostatin and GnRH Analogues and Their Applications in Tumor Therapy

Curr Drug Deliv. 2022;19(1):5-16. doi: 10.2174/1567201819666211224113311.

Abstract

Hormonal drugs are essential treatment options for some hormone-dependent or hormone- sensitive tumors. The common dosage forms of hormonal drugs have a short half-life. Hence, frequent administration is needed, which results in poor patient compliance. Nevertheless, using drug delivery technology, somatostatin analogues (SSAs) and gonadotropin-releasing hormone (GnRH) analogues are prepared into long-acting formulations that can significantly prolong the action time of these drugs, reducing medication frequency and increasing patient compliance. Such drugs are advantageous when treating acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NETs), breast cancer, prostate cancer, and other diseases having a relatively long course. SSAs and GnRH analogues are two typical hormonal drugs, the long-acting formulations of which are essential in clinical practice. This review summarized the preparation methods and clinical application of long-acting formulations in cancer. Further, the action mechanism and new research of SSAs and GnRH analogues were discussed, and suggestions related to the development of long-acting SSAs and GnRH analogues were provided.

Keywords: GnRH analogues; Hormonal drugs; hormone-sensitive tumors; long-acting analogues; somatostatin analogues; tumor therapy.

Publication types

  • Review

MeSH terms

  • Gonadotropin-Releasing Hormone
  • Humans
  • Intestinal Neoplasms* / drug therapy
  • Neuroendocrine Tumors* / drug therapy
  • Neuroendocrine Tumors* / pathology
  • Pancreatic Neoplasms* / drug therapy
  • Somatostatin / therapeutic use

Substances

  • Gonadotropin-Releasing Hormone
  • Somatostatin